Primient and Synonym Partner to Boost Bioproduct Innovation & Commercialization in the US
Primient, established in 2022 when Tate & Lyle sold a controlling stake in its Primary Products business to KPS Capital Partners (with the $350M sale completing just this May), has formed a strategic partnership with Synonym, a biomanufacturing infrastructure developer, to boost bioproduct innovation and commercialization. The partnership leverages Primient’s experience in renewable, plant-based ingredients, and Synonym’s biomanufacturing platforms and aims to accelerate the development of new, functional, and affordable biomaterials in the USA. “The partnership breaks new ground for how companies of all sizes can model, prove out, de-risk, and scale up functional, biobased products using precision fermentation which are better for people and planet,” states Primient on its social channels. “It is a match made to fast-track bioproduct launches and fuel the U.S. …